Skip to main navigation Skip to search Skip to main content

Enhanced antigen cross-presentation in human colorectal cancer-associated fibroblasts through upregulation of the lysosomal protease cathepsin S

  • Tom J. Harryvan
  • , Marten Visser
  • , Linda De Bruin
  • , Léonie Plug
  • , Lisa Griffioen
  • , Arend Mulder
  • , Peter A. Van Veelen
  • , Gerbrand J. Van Der Heden Van Noort
  • , Marlieke L.M. Jongsma
  • , Miranda H. Meeuwsen
  • , Emmanuel J.H.J. Wiertz
  • , Saskia J. Santegoets
  • , James C.H. Hardwick
  • , Thorbald Van Hall
  • , Jacques Neefjes
  • , Sjoerd H. Van Der Burg
  • , Lukas J.A.C. Hawinkels
  • , Els M.E. Verdegaal*
  • *Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

3 Citations (Scopus)
11 Downloads (Pure)

Abstract

Background Cross-presentation of exogenous antigens in HLA-class I molecules by professional antigen presenting cells (APCs) is crucial for CD8+ T cell function. Recent murine studies show that several non-professional APCs, including cancer-associated fibroblasts (CAFs) also possess this capacity. Whether human CAFs are able to cross-present exogenous antigen, which molecular pathways are involved in this process and how this ultimately affects tumor-specific CD8+ T cell function is unknown. Methods In this study, we investigated the ability of human colorectal cancer (CRC)-derived CAFs to cross-present neoantigen-derived synthetic long peptides (SLPs), corresponding to tumor-derived mutant peptides, and how this affects tumor-specific T-cell function. Processing of the SLP was studied by targeting components of the cross-presentation machinery through CRISPR/Cas9 and siRNA-mediated genetic ablation to identify the key molecules involved in fibroblast-mediated cross-presentation. Multispectral flow cytometry and killing assays were performed to study the effect of fibroblast cross-presentation on T cell function. Results Here, we show that human CRC-derived CAFs display an enhanced capacity to cross-present neoantigen-derived SLPs when compared with normal colonic fibroblasts. Cross-presentation of antigens by fibroblasts involved the lysosomal protease cathepsin S. Cathepsin S expression by CAFs was detected in situ in human CRC tissue, was upregulated in ex vivo cultured CRC-derived CAFs and showed increased expression in normal fibroblasts after exposure to CRC-conditioned medium. Cognate interaction between CD8+ T cells and cross-presenting CAFs suppressed T cell function, reflected by decreased cytotoxicity, reduced activation (CD137) and increased exhaustion (TIM3, LAG3 and CD39) marker expression. Conclusion These data indicate that CAFs may directly suppress tumor-specific T cell function in an antigen-dependent fashion in human CRC.

Original languageEnglish
Article numbere003591
JournalJournal for immunotherapy of cancer
Volume10
Issue number3
DOIs
Publication statusPublished - 9 Mar 2022

Keywords

  • antigen presentation
  • gastrointestinal neoplasms
  • immunotherapy

Fingerprint

Dive into the research topics of 'Enhanced antigen cross-presentation in human colorectal cancer-associated fibroblasts through upregulation of the lysosomal protease cathepsin S'. Together they form a unique fingerprint.

Cite this